Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Novel Inflammatory Pathways in Chronic Human Liver Diseases

WEBINAR

Only

Novel Inflammatory Pathways in Chronic Human Liver Diseases

Tuesday, October 20, 2020, 8:30 AM - 5:00 PM EDT

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

The New York Academy of Sciences

 

Non-alcoholic fatty liver disease (NAFLD) affects 25% of the world population. Many of these patients subsequently develop non-alcoholic steatohepatitis (NASH), a progressive chronic liver disease for which there is no approved treatment. NASH is projected to be the leading cause of liver failure and transplant in the coming decades. Inflammatory and pro-fibrotic pathways are wells established drivers of NASH progression; however, recent work has identified additional cell types as novel regulators of these pathways. Thus, this symposium will focus on less studied immune lineages — such as T helper cells, innate lymphoid cells (ILCs), and natural killer (NK) cells, as well as other non-traditional cell types — including fibroblasts, liver sinusoidal endothelial cells (LSECs), and hepatocytes, which are emerging as critical contributors to NAFLD and NASH. The overarching aim of the meeting is to highlight novel mechanisms that may present new therapeutic targets for chronic liver diseases.

Call for Abstracts

Abstract submissions are invited for a poster session and short talks. For complete submission instructions, please visit our online portal. The deadline for abstract submission is Tuesday, August 18, 2020.

Registration

Member
$30
Nonmember Academia, Faculty, etc.
$65
Nonmember Corporate, Other
$85
Nonmember Not for Profit
$65
Nonmember Student, Undergrad, Grad, Fellow
$45
Member Student, Post-Doc, Fellow
$15

Keynote Speaker

Tim F. Greten, MD
Tim F. Greten, MD

National Cancer Institute

Speakers

Laurie De Leve, MD, PhD

University of Southern California

Percy Knolle, MD

Technische Universität München

Mitchell Kronenberg, PhD

La Jolla Institute for Immunology

Paul Kubes, PhD

University of Calgary

Sophie Lotersztajn, PhD

Center for Research on Inflammation, Paris

Naglaa Shoukry, PhD

University of Montreal

Scientific Organizing Committee

Tim F. Greten, MD

National Cancer Institute

Kevin Hart, PhD

Pfizer

Min Wan, PhD

Pfizer

Sara Donnelly, PhD

The New York Academy of Sciences

Sonya Dougal, PhD

The New York Academy of Sciences